Some areas of the world or must be waiting for one year to get Pfizer Crown Disease Or

(Bloomberg, London) The Pharmaceutical Penal Pool Organization supported by the United Nations will announce the list of pharmaceutical companies that have been approved by Paxlovid for the Phaxlovid.However, due to the obstacles of production and supervision, some areas of the world may have to wait a year to obtain the drug.

The Medicinespatentpool (MPP) reached a license agreement with Pfizer four months ago, which can authorize qualified generic drug manufacturers to produce PAXLOVID so that the global population can get new crown therapy drugs faster.

MPP said that the pharmaceutical dealers are expected to produce the first batch of PAXLOVID in December this year.However, according to an analysis company Airfinity estimates, it may not be more out of production into the market until May 2023.

Clinical trials show that PAXLOVID can reduce the probability of hospitalization or death by patients with crown diseases nearly 90%.Due to the high efficacy, the demand for this drug is expected to exceed the supply.

As of now, the initial supply of PaxLovid has been booked by a richest country.This has brought increasing pressure on Pfizer and other companies, and they must speed up PAXLOVID in low -income countries that are difficult to obtain vaccine.

PaxLovid consists of two pills, one is Nirmatrelvir, which can block the activity of the new coronary virus 3CL protease and prevent virus replication; the other pill is Ritonavir), It can slow down Nimarine's decomposition to help it maintain longer activity at a higher concentration.

MPP pointed out that the public information about Nirmatrelvir is relatively limited, and manufacturers must wait for the license and obtain the original product of Pfizer.

Goror, executive director of MPP, said that some inevitable obstacles and complexity takes time to solve, including waiting for the approval of regulatory agencies, and Paxlovid confirmed that it can be effective for a long time.

Production facing another potential challenge is to get raw materials

Senior Researcher Hill University in Liverpool in the United Kingdom said that another potential challenge faced by PaxLovid isGet raw materials.According to Airfinity, during the production of the drug, 38 different raw materials and reagents must be purchased from suppliers around the world. Although there is no known shortage at present, bottlenecks may occur in the future.